Summary
Abbott Laboratories reported net sales of $5.55 billion for the second quarter ended June 30, 2014, a 1.9% increase year-over-year, with international sales showing stronger growth than domestic sales. This increase, excluding the impact of foreign exchange, was 3.0%. The company's earnings from continuing operations were $460 million, or $0.30 per diluted share, reflecting a slight decrease from the prior year period. Management highlighted positive sales trends in Diagnostic Products and Vascular Products segments, with the latter benefiting from the launch of the Absorb bioresorbable vascular scaffold and Supera endovascular product. However, Established Pharmaceutical Products saw a slight sales decline, partly due to pricing pressures and foreign exchange headwinds, while Nutritional Products were impacted by a prior supplier recall. Financially, Abbott maintained a solid liquidity position with $3.57 billion in cash and cash equivalents. The company continued its commitment to shareholder returns, significantly increasing its quarterly dividend by 57% to $0.22 per share. Strategic growth initiatives are underway, with significant pending acquisitions in Latin America (CFR Pharmaceuticals) and Russia (Veropharm), alongside the announced sale of its developed markets branded generics business to Mylan. These strategic moves indicate a focus on portfolio optimization and geographic expansion.
Financial Highlights
52 data points| Revenue | $5.06B |
| Cost of Revenue | $2.29B |
| Gross Profit | $2.64B |
| SG&A Expenses | $1.65B |
| Operating Expenses | $4.38B |
| Operating Income | $677.00M |
| Interest Expense | $36.00M |
| Net Income | $466.00M |
| EPS (Basic) | $0.30 |
| EPS (Diluted) | $0.30 |
| Shares Outstanding (Basic) | 1.51B |
| Shares Outstanding (Diluted) | 1.52B |
Key Highlights
- 1Net sales increased by 1.9% to $5.55 billion in Q2 2014, driven by a 3.0% increase excluding foreign exchange impacts.
- 2Earnings from continuing operations were $460 million ($0.30 per diluted share), a slight decrease from $476 million in the prior year.
- 3The company announced a substantial 57% increase in its quarterly dividend to $0.22 per share.
- 4Strategic acquisitions are underway, including CFR Pharmaceuticals in Latin America for approximately $2.9 billion and Veropharm in Russia for approximately $395-$495 million.
- 5Abbott announced the sale of its developed markets branded generics pharmaceuticals business to Mylan for approximately $5.3 billion, expected to close in Q1 2015.
- 6Goodwill remained stable at $9.75 billion, with no impairment charges recorded.
- 7Restructuring charges of $80 million were recorded in the first six months of 2014 to streamline operations.